GLP-1 Semaglutide Fails to Slow Alzheimers Despite Biomarker Changes The GLP-1 drug semaglutide failed to treat Alzheimers across two large trials despite lowering the levels of some Alzheimers-related biomarkers
In Model 2, higher ProBDNF levels were associated with cocaine use (a = 23.59, 95% CI: 3.6943.49, p = 0.023), psychopharmaceutical intake (a = 42.71, 95% CI: 19.9565.46, p = 0.001), and previous psychiatric hospitalization (a = 60.64, 95% CI: 27.0194.26, p = 0.001), whereas a previous psychiatric diagnosis was negatively associated with the outcome (a = 43.43, 95% CI: 66.76 to 20.10, p = 0.001)
The mechanism behind these effects is often attributed to the direct or indirect antioxidant activity of NAC and redox regulation of signal transduction, including WNT/-catenin, TP53, and PI3K/AKT pathways
If you are using a regular cooler as a backup, wrap the tirzepatide vial or pen in a cloth and place it in the center of the cooler, away from ice or frozen packs